-

11:31:31 PM

SKYE Stock News

SKYE - Skye Bioscience Inc

06/02/23 7:00 AM

OTC : SKYE

clinical trial

Skye Bioscience Receives Positive Safety Review of Fifth Cohort of Phase 1 Study of SBI-100 Ophthalmic Emulsion

Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reports that the

RHEA-AI

neutral

05/17/23 7:00 AM

OTC : SKYE

clinical trial

Skye Bioscience Begins Dosing Fifth of Six Cohorts in Phase 1 Clinical Trial of Novel CB1R Agonist

Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat

RHEA-AI

neutral

05/15/23 7:00 AM

OTC : SKYE

clinical trial

Skye Bioscience Receives Positive Safety Review in First Multiple-Administration Cohort of Phase 1 Study of SBI-100 Ophthalmic Emulsion

Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reports that the safety review committee ("SRC") for its Phase 1 clinical

RHEA-AI

negative

09/20/22 7:00 AM

OTC : SKYE

clinical trial

Skye Bioscience Completes Drug Production for Phase 1 Clinical Study

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer (“CMO”) that it has

RHEA-AI

neutral

09/01/22 7:00 AM

OTC : SKYE

Skye Bioscience Files Definitive Proxy Statement and Announces Stockholder Meeting Date

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, announces that it has filed its definitive proxy statement related to

RHEA-AI

neutral

08/19/22 3:22 PM

OTC : SKYE

Skye Bioscience Reports that Emerald Health Therapeutics Shareholders Voted in Favor of Plan of Arrangement with Skye

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reports that the shareholders of Emerald Health Therapeutics, Inc.

RHEA-AI

very positive

07/21/22 7:00 AM

OTC : SKYE

clinical trial

Skye Bioscience Selects NextPharma as Phase 2 Contract Drug Manufacturer

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to

RHEA-AI

neutral

07/20/22 7:00 AM

OTC : SKYE

clinical trial

Skye Bioscience Updates Phase 1 Timeline

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer (“CMO”) of its Phase 1

RHEA-AI

neutral

06/07/22 7:00 AM

OTC : SKYE

Skye Bioscience Expands Cannabinoid Pharmaceutical Innovation Program with Leading Cannabinoid Medicinal Chemistry Groups

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company

RHEA-AI

positive

05/12/22 9:05 AM

OTC : SKYE

Skye Bioscience Signs Arrangement Agreement with Emerald Health Therapeutics

Arrangement is expected to fund Skye’s proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first Phase 2 clinical study planned to start later in 2022 Preclinical studies have demonstrated potential advantages of Skye’s unique, patent-protected therapeutic

RHEA-AI

very positive